[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=c05e503865965d7e36e0834b637f452c54f26b22a21b31cf0a4b075be1d19620",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746808620,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "id": 134386171,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=c05e503865965d7e36e0834b637f452c54f26b22a21b31cf0a4b075be1d19620"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment",
    "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell […]",
    "url": "https://finnhub.io/api/news?id=d57a25ab1e3d478d34748c33909127bd86ce59832dd0c41929fc6c03e12d09f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746799415,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment",
      "id": 134362413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell […]",
      "url": "https://finnhub.io/api/news?id=d57a25ab1e3d478d34748c33909127bd86ce59832dd0c41929fc6c03e12d09f4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=a51f53dc461dd6aaaacae7ca59d529a11d4bcaefa2d96db1fd951ba2d7b2da29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746795611,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
      "id": 134362414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=a51f53dc461dd6aaaacae7ca59d529a11d4bcaefa2d96db1fd951ba2d7b2da29"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now",
    "summary": "It's shaping up to be a tough period for Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ), which a week ago released...",
    "url": "https://finnhub.io/api/news?id=f021c0ee6a60a07d63dbc9fffed55f7b67d923db25dbd3bf23369f4f51a84467",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746787498,
      "headline": "Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now",
      "id": 134335948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "It's shaping up to be a tough period for Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ), which a week ago released...",
      "url": "https://finnhub.io/api/news?id=f021c0ee6a60a07d63dbc9fffed55f7b67d923db25dbd3bf23369f4f51a84467"
    }
  },
  {
    "ts": null,
    "headline": "4 No-Brainer Stocks to Buy Right Now",
    "summary": "The current volatile situation shouldn't preclude investors from buying stocks.  Eli Lilly, Vertex, Meta Platforms, and Netflix all stand to enjoy solid growth.  Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time.",
    "url": "https://finnhub.io/api/news?id=a5f5c6b1d757b5921fd582c265884aec020450fa897231e4ecd771e644560f9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746786600,
      "headline": "4 No-Brainer Stocks to Buy Right Now",
      "id": 134335710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The current volatile situation shouldn't preclude investors from buying stocks.  Eli Lilly, Vertex, Meta Platforms, and Netflix all stand to enjoy solid growth.  Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time.",
      "url": "https://finnhub.io/api/news?id=a5f5c6b1d757b5921fd582c265884aec020450fa897231e4ecd771e644560f9e"
    }
  },
  {
    "ts": null,
    "headline": "Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines",
    "summary": "CRISPR Therapeutics benefits from Casgevyâs approval and a deep pipeline, despite early rollout hurdles and cost challenges. Learn why CRSP stock is a buy.",
    "url": "https://finnhub.io/api/news?id=1d9e03549d0bacced8f28f55c42d7c4372be8740d8a7d5366ca8540cbbcb44cb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746774890,
      "headline": "Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines",
      "id": 134335893,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411308864/image_1411308864.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "CRISPR Therapeutics benefits from Casgevyâs approval and a deep pipeline, despite early rollout hurdles and cost challenges. Learn why CRSP stock is a buy.",
      "url": "https://finnhub.io/api/news?id=1d9e03549d0bacced8f28f55c42d7c4372be8740d8a7d5366ca8540cbbcb44cb"
    }
  },
  {
    "ts": null,
    "headline": "Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).",
    "url": "https://finnhub.io/api/news?id=c23a8c9a47043b7709c88b614cf6723f3c69605ae4e91d4ce75f86cad1b4c7ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746761460,
      "headline": "Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks",
      "id": 134362266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).",
      "url": "https://finnhub.io/api/news?id=c23a8c9a47043b7709c88b614cf6723f3c69605ae4e91d4ce75f86cad1b4c7ff"
    }
  }
]